Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Promising Dementia Treatment Trial: Coya Therapeutics Completes Key FTD Study Enrollment with Zero Safety Issues

Summary by stocktitan.net
Biotech firm Coya enrolls 9 patients in Frontotemporal Dementia treatment study combining IL-2 and CTLA4-Ig. Following positive interim data, final results expected Q4 2025.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

Clinical Trials ArenaClinical Trials Arena

Coya completes FTD combination therapy trial enrolment

Coya Therapeutics has completed enrolment of a trial evaluating low-dose IL-2 and CTLA4-Ig treatment in subjects with mild to moderate FTD.The post Coya completes FTD combination therapy trial enrolment appeared first on Clinical Trials Arena.

Read Full Article
stocktitan.netstocktitan.net

Promising Dementia Treatment Trial: Coya Therapeutics Completes Key FTD Study Enrollment with Zero Safety Issues

Biotech firm Coya enrolls 9 patients in Frontotemporal Dementia treatment study combining IL-2 and CTLA4-Ig. Following positive interim data, final results expected Q4 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

stocktitan.net broke the news on Monday, September 29, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal